Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: A multidimensional statistical approach

Journal of Nuclear Medicine

Volumn 52, Issue 5, 2011, Pages 733-740

  Südmeyer, Martin ^a,b   Antke, Christina ^b   Zizek, Tanja ^a   Beu, Markus ^b   Nikolaus, Susanne ^b   Wojtecki, Lars ^a   Schnitzler, Alfons ^a   Müller, Hans Wilhelm ^b  

^a Department of Orthopedic Surgery   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Atypical parkinsonian disorder; FP CIT; IBZM; MIBG; Parkinson disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; IOFLUPANE I 123; LEVODOPA; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE I 123; TRACER; UNCLASSIFIED DRUG;

ADRENERGIC NERVE; ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DRUG RESPONSE; HEART INNERVATION; HUMAN; IN VIVO STUDY; PARKINSON DISEASE; PARKINSONISM; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; ADULT; AGED; ALGORITHMS; BENZAMIDES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MIDDLE AGED; PARKINSON DISEASE; PARKINSONIAN DISORDERS; PYRROLIDINES; RADIONUCLIDE IMAGING; ROC CURVE; SENSITIVITY AND SPECIFICITY; TROPANES;

EID: 79955756270     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.086959     Document Type: Article

References (41)

1. Poewe W. Clinical measures of progression in Parkinson's disease. Mov Disord. 2009;24(suppl 2):S671-S676.
2. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 2009;8:1150-1157.
3. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125:861-870. (Pubitemid 34279780)
4. Scherfler C, Nocker M. Dopamine transporter SPECT: how to remove subjectivity? Mov Disord. 2009;24(suppl 2):S721-S724.
5. Felicio AC, Shih MC, Godeiro-Junior C, Andrade LA, Bressan RA, Ferraz HB. Molecular imaging studies in Parkinson disease: reducing diagnostic uncertainty. Neurologist. 2009;15:6-16.
6. Nikolaus S, Antke C, Kley K, et al. Investigating the dopaminergic synapse in vivo: I. Molecular imaging studies in humans. Rev Neurosci. 2007;18:439-472.
7. Nikolaus S, Antke C, Muller HW. In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia. Behav Brain Res. 2009;204:1-31.
8. 18F-desmethoxyfallypride for the differentiation of idiopathic and non-idiopathic parkinsonian syndromes. J Nucl Med. 2010;51:581-587.
9. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord. 2002;17:303-312.
10. Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol. 2007;7:27.
11. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) - report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:968-975. (Pubitemid 44044778)
12. 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm. 2005;112:677-692.
13. 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol. 2008;59:258-266.
14. Koch W, Hamann C, Radau PE, Tatsch K. Does combined imaging of the preand postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism? Eur J Nucl Med Mol Imaging 2007;34:1265-1273.
15. Sawada H, Oeda T, Yamamoto K, et al. Diagnostic accuracy of cardiac meta-iodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol. 2009;16:174-182.
16. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18:738-750.
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181-184.
18. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163:94-98. (Pubitemid 29155424)
19. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670-676.
20. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1-9. (Pubitemid 26243849)
21. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1996;60:615-620. (Pubitemid 26237111)
22. 2 transporter ligands. Eur J Nucl Med Mol Imaging. 2002;29:BP30-BP35.
23. 2 receptor ligands. Eur J Nucl Med Mol Imaging. 2002;29:BP23-BP29.
24. Chang L. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978;NS-25:638-643.
25. Brooks DJ. Imaging dopamine transporters in Parkinson's disease. Biomarkers Med. 2010;4:651-660.
26. 123I]β-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord. 2001;16:1023-1032.
27. Antonini A, Benti R, De NR, et al. 123I-ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci. 2003;24:149-150. (Pubitemid 37304286)
28. Spiegel J, Mollers MO, Jost WH, et al. FP-CIT and MIBG scintigraphy in early Parkinson's disease. Mov Disord. 2005;20:552-561. (Pubitemid 40862252)
29. Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal β-CIT SPECT study. Mov Disord. 2002;17:45-53. (Pubitemid 36041259)
30. 123I]β-CIT SPECT analysis. Arch Neurol. 2006;63:1154-1160.
31. 123I]β-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease. Eur J Nucl Med Mol Imaging. 2005;32:689-695.
32. 123I] β-CIT and SPECT: correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997;50:9-24.
33. 123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266-272.
34. Knudsen GM, Karlsborg M, Thomsen G, et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging. 2004;31:1631-1638. (Pubitemid 40104609)
35. 123I]β-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain. 2005;128:1605-1612.
36. Larisch R, Klimke A. Clinical impact of cerebral dopamine-D2 receptor scintigraphy [in German]. Nuklearmedizin. 1998;37:245-250. (Pubitemid 28525303)
37. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res. 2001;11:351-355. (Pubitemid 34461714)
38. 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med. 1999;40:371-375.
39. Yoshita M. Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci. 1998;155:60-67. (Pubitemid 28141060)
40. 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord. 2009;24(suppl 2):S732-S741.
41. Druschky A, Hilz MJ, Platsch G, et al. Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci. 2000;175:3-12. (Pubitemid 30227477)